Helion Biotech ApS

Phase II ready project available for Partnering

- Restoration of inherited immune defect by replacement therapy with recombinant human mannan-binding lectin (rhMBL)

- More than 10 independent publications since 2006 identify MBL deficiency as a very strong risk factor for neonatal infection and sepsis

- Complete US regulatory dossier allows for bridging directly into a Phase II clinical trial, targeting MBL deficient very preterm neonates

- Option exist for subsequent commercial expansion in other immunocompromised individuals

Mannan-Binding Lectin (MBL) is a key component of the innate immune defence. It is responsible for activation of the complement system upon binding to carbohydrate structures widely present on bacteria, viruses and fungi. MBL therefore plays a key role in the first line immune defence against invading pathogens.

MBL defienciencies exist, which result in increased risk of infections in certain high-risk populations. Reconstitution of this immune defect by replacement therapy with recombinant human MBL is warranted for prevention of infections in such patient populations.

Mannan-Binding Lectin Associated Serine Protease 2 (MASP-2) is the enzyme responsible for activation of the complement system mediated by MBL following binding to carbohydrates on the surface of microorganisms.

Helion Biotech ApS

MBL defienciencies exist, which result in increased risk of infections in certain high-risk populations. Reconstitution of this immune defect by replacement therapy with recombinant human MBL is warranted for prevention of infections in such patient populations.

Inhibition of MASP-2 is currently being explored in certain inflammatory conditions hereunder AMD, transplantation, and ischemic reperfusion injury.